Cover Story: Europe’s Medicine Man
Pharm Exec meets with Dr. Guido Rasi, Executive Director of the European Medicines Agency – and the man responsible for the review and registration of new drugs used by more than 500 million patients in the 27 nation European Union, the world’s largest market for medicines. Dr. Rasi shares with readers his priorities in an era of globalization and suggests ways the R&D industry can improve its reputation through support for “smart” regulation, in partnership with patients and health professionals as well as the regulatory community.

Strategy Profile: Partnering for Clinical Development
In a Pharm Exec exclusive, executives detail initial results from Eli Lilly’s new partnership with CRO leader Covance in seeking improved efficiencies from the management of clinical development in key therapeutic segments important to the company. Among the questions answered are designing ground rules for a productive, trustful relationship and identifying gaps in procedures that act as a drag on speed-to-market planning.

Market access Updates: Germany and Turkey
Fresh input from the field, with two features covering the state of market access for medicines in Germany, where a controversial new value-based price reform law is now fully in force, and in Turkey, whose positive demographics around market demand are diluted by controversial measures to slow decisions on authorization and reimbursement for the new medicines offered by foreign multinationals. Both countries are bellwethers of change, and their reform approach is being watched closely by many other countries worldwide. We bring you the full picture on the premise that to act globally, you must think local first.

Finally, we round out the year with columns that examine the industry fallout from the US presidential elections.